A recent study of FLT3 testing behavior in relapsed acute myeloid leukemia (AML) conducted by experts at Diaceutics has uncovered the need for faster laboratory testing turnaround times (TAT). CTO at Diaceutics, Jordan Clark discussed the findings with OncLive at this year’s EHA Congress where the abstract was accepted for publication. The abstract analyzes the FLT3 testing behavior in relapsed acute myeloid leukemia (AML) over the course of a year. Read the full abstract here
Diaceutics is a data analytics and implementation services business for major pharmaceutical companies. The company is transforming an industry model by enabling pharma to accelerate their market penetration and achieve a better return on new therapies by helping them to revolutionise their patient testing. It does this by providing insights generated from its vast data lake consisting of real time diagnostic testing data gather from clinical laboratories around the world. Diaceutics’ services help pharma to understand and leverage the diagnostic landscape and deploy initiatives that improve patient diagnosis. The company has experience of more than 300 precision medicine projects and works with 33 of the world’s top 35 pharmaceutical companies. The company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.